Skip to main content

Market Overview

UPDATE: Credit Suisse Initiates Coverage on Mediwound Ltd. for Filling Unmet Need in Burns


In a report published Monday, Credit Suisse analyst Bruce Nudell initiated coverage on Mediwound Ltd. (NASDAQ: MDWD) with an Outperform rating and $18.00 price target.

In the report, Credit Suisse noted, “MDWD is an Israeli therapeutics company with one approved product, NexoBrid (NXB) for severe burns, launching in Europe in 2014, with US approval expected by 2019. Nexobrid fills an unmet medical need in burns in what we see as a ~$400M market opportunity. The company is also in trials with the active ingredient in Nexobrid in the much larger chronic wound opportunity.”

Mediwound Ltd. closed on Friday at $11.71.

Latest Ratings for MDWD

Mar 2021Aegis CapitalInitiates Coverage OnBuy
Sep 2020BTIGInitiates Coverage OnBuy
Aug 2019H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for MDWD
View the Latest Analyst Ratings


Related Articles (MDWD)

View Comments and Join the Discussion!

Posted-In: Bruce Nudell Credit SuisseAnalyst Color Initiation Analyst Ratings

Latest Ratings

CMRXHC Wainwright & Co.Maintains18.0
PZZAStephens & Co.Maintains115.0
STAACanaccord GenuityMaintains150.0
DGIICanaccord GenuityMaintains25.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at